Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratoy failure in patients suffering from COVID-19.
Information on the Annual Financial Statements Biophytis announces that it is not in a position to publish its 2024 annual accounts on the previously scheduled date. Biophytis will publish its 2024 annual accounts as soon as possible, by Monday, July 7 at the latest. Fullscreen Mode
Biophytis announces the temporary suspension of the trading of its shares Biophytis announces the temporary suspension of the trading of its shares by Euronext, due to the non-publication of its annual financial report for the fiscal year ended December 31, 2024. The report will be published following certification of the…
Biophytis announces its participation in the BIO International Convention from June 16 to 19 Biophytis announces its participation to the BIO International Convention, which will take place this year in Boston, USA, from June 16 to 19, 2025. Edouard Bieth, Chief Strategy Officer at Biophytis, will be present and will…
Information on the Annual Financial Statements Biophytis announces that, due to exceptional circumstances related to technical complications in the audit process, the publication of its 2024 annual financial statements has been postponed. The Company requires additional time to complete the audit and certification of its accounts. As a result, Biophytis…
Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 2025 Presentation Biophytis announced its active participation at the 32nd European Congress on Obesity (ECO 2025), held from May 11 to 14 in Malaga, Spain. During this premier international event, which brings together leading experts, clinicians, researchers, and industry stakeholders…
Postponement of the publication of the annual financial statements Biophytis announces the postponement of the publication of its annual financial statements for the year ended December 31, 2024. Due to the €2.6 million refinancing operation (announced in the press release dated March 26, 2025), the Company had to focus its…
Biophytis targets mobility restoration in patients with obesity Biophytis strentghens its position as one of the leading players in preserving muscle function in patients with obesity treated with GLP-1 therapies. While these treatments are revolutionizing obesity care by delivering significant weight loss, they also induce a concerning loss of muscle…
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity Biophytis confirms the launch of the Phase 2 OBA clinical study in obesity, expected to begin as early as possible in 2025. Following the recent €2.6 million capital increase announced on March 26, 2025, and promising preclinical…
Biophytis announces the settlement and delivery of its €2.6 million private placement NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA Biophytis announces today the settlement and delivery of its private placement in the amount of €2,599,979.72 (including the issuance premium),…
Biophytis announces the successful completion of a €2,6 million private placement Capital increase of a total amount of approximately €2,6 million in gross proceeds by issuing 4,307,614 new shares, each with one share warrant attached, at €0,26 per unit, and 5,692,308 pre-funded warrants, each with one share warrant attached, at…
Biophytis announces new non-clinical data further supporting its mission to pioneer the restoration of mobility in patients with obesity 96% of patients with obesity report experiencing muscle strength impairment, affecting their mobility. New preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and mobility restoration in animal…
Biophytis revolutionizes sarcopenia Biophytis is excited to announce a world premiere: the publication of the Phase 2 clinical trial SARA-INT in the Journal of Cachexia, Sarcopenia and Muscle (JCSM), the key reference journal for research on sarcopenia. Key BIO101 Attributes from the SARA INT Trail include: Promising Efficacy: BIO101 350mg…
Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.
Our lead drug candidate, BIO101 (20-hydroxyecdysone), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.
BIOPHYTIS ON THE STOCK MARKET
Biophytis has been listed on the market Euronext Growth Paris since July 13, 2015.
ISIN FR001400OLP5
Ticker: ALBPS
Type of listing: continuous
Total number of shares at 31/05/2025: 20,165,736
1 ADR = 10 shares
Number of voting rights at 31/05/2025: 20,200,219
Eligible for PEA and PEA-PME equity saving plans
Click here for live stock price